Functional Neuromodulation
Functional Neuromodulation is a privately held Toronto-based medical technology company, founded in 2010, developing neuromodulation technologies for cognitive and memory disorders within the deep brain stimulation device market.
- Company typePrivate
- Founded2010
- HeadquartersToronto, Canada
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Functional Neuromodulation does
Functional Neuromodulation is a privately held medical technology company founded in 2010 and headquartered in Toronto, Canada, that is developing neuromodulation technologies targeting cognitive and memory disorders. The company's work sits within the deep brain stimulation (DBS) device market, which independent market intelligence projects will reach $2.94 billion by 2030 at an 11.6% annual growth rate, suggesting a substantial long-term addressable opportunity for cognitive-indication neuromodulation. The company is scientifically anchored by Dr. Andres Lozano, who serves as Founding Scientist, Chairman of the Scientific Advisory Board, and Director — a leadership structure typical of academic spin-out ventures translating deep brain stimulation research into clinical applications.
The company's only disclosed financing to date was a $10.4 million round closed in October 2011, led by Medtronic with participation from Genesys Capital. The involvement of Medtronic, the dominant incumbent in DBS hardware, is strategically significant and may indicate a future commercial partnership, licensing pathway, or acquisition route. With 1-10 employees and no publicly disclosed product, pricing, customer base, or revenue, the company appears to operate as a small, research- and clinical-stage organization rather than a commercial entity.
No product specifications, regulatory milestones, clinical trial readouts, intellectual property portfolio, geographic footprint, or go-to-market details are present in the available source material. As a result, the company's current stage of development, burn rate, pipeline composition, and commercialization timeline cannot be verified from public information alone. Investors evaluating Functional Neuromodulation should treat it as a thinly disclosed, early-stage clinical venture and seek primary information from the company, clinical trial registries, and regulatory filings before forming a view on execution risk.
Functional Neuromodulation firmographics
Firmographics- Name
- Functional Neuromodulation
- Website
- https://fxneuromod.com
- Company type
- Private
- Founded year
- 2010
- Headcount range
- 1–10 employees
- Short description
- Functional Neuromodulation is a privately held Toronto-based medical technology company, founded in 2010, developing neuromodulation technologies for cognitive and memory disorders within the deep brain stimulation device market.
- Ownership category
- akta.pro rank
Functional Neuromodulation industry classification
Industry- Product category
- Deep Brain Stimulation Devices
- NAICS
- Scientific Research and Development Services (5417)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS) (HLAHAEAK)
Keywords
Where Functional Neuromodulation is headquartered
LocationHeadquarters
- HQ city
- Toronto
- HQ country
- Canada
- HQ region
- North America
Markets served
Functional Neuromodulation business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Functional Neuromodulation product offering
Product offeringCore offering
Functional Neuromodulation is a medical technology company developing neuromodulation technologies targeting cognitive and memory disorders. The company focuses on deep brain stimulation (DBS) approaches intended to treat conditions such as Alzheimer's disease and related cognitive impairments. The firm operates in the DBS device market, which is projected to reach $2.94 billion by 2030 at an 11.6% annual growth rate.
Product overview
No product or service information is available from the provided sources. The available source data consists of a limited webpage fragment (tracking pixel and cookie consent link only) and two market-context news articles about the deep brain stimulation device market, which do not contain specific product details for Functional Neuromodulation.
Differentiator
Problem solved
Functional benefit
Products and services
- Deep Brain Stimulation (DBS) Technology for Cognitive Disorders Neuromodulation technology platform targeting cognitive and memory disorders such as Alzheimer's disease, intended for use by clinicians and patients with cognitive impairments, developed within the deep brain stimulation device market.
Companies that use Functional Neuromodulation
Customer profileIdeal customer profiles2 records
Functional Neuromodulation technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Functional Neuromodulation partnerships and signals
Strategic signalScale indicators1 record
Recent moves3 records
Expansion highlights2 records
Functional Neuromodulation competitors and assessment
Company assessmentBroad incumbents
- Abbott: Through its St. Jude acquisition, Abbott markets the Infinity DBS system. A primary DBS incumbent with comparable neurostimulation infrastructure and R&D programs.
- Medtronic: Global leader in implantable DBS systems (Activa) and lead investor in Functional Neuromodulation's 2011 round. Direct incumbent in DBS hardware with overlapping cognitive-disorder research interests.
- Boston Scientific: Markets the Vercise DBS system and is actively investing in next-generation directional and sensing-enabled DBS. Another top-3 DBS incumbent competing for cognitive-indication opportunities.
- MicroPort Scientific: Acquired LivaNova's CRM/neuromodulation business and continues to develop DBS systems (e.g., Beijing Puhua license). Comparable as a broad incumbent now competing in the DBS market.
Direct peers
- NeuroPace: Develops the RNS System, an implantable closed-loop neurostimulator for epilepsy. Comparable as a venture-backed, indication-focused implantable brain neuromodulation company.
- LivaNova: Markets Vagus Nerve Stimulation (VNS) systems for epilepsy and treatment-resistant depression. Comparable as an implantable neuromodulation company pursuing CNS indications adjacent to cognition/behavior.
Emerging players
- Inspire Medical Systems: Implantable neurostimulation (hypoglossal nerve stimulation) for obstructive sleep apnea. Comparable as a venture-backed implantable neurostim developer that scaled from small team to public company.
- Axonics: Develops sacral neuromodulation implants for incontinence. Comparable as a focused, venture-backed implantable neurostimulation company pursuing a specific high-unmet-need indication.
- Nevro: Markets 10 kHz high-frequency spinal cord stimulation systems for chronic pain. Comparable as an implantable neurostimulation company focused on a specific therapeutic application.
- SetPoint Medical: Developing bioelectronic VNS therapy for inflammatory autoimmune diseases. Comparable as a venture-backed company applying implantable neurostimulation to non-traditional indications.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Functional Neuromodulation social profiles
Digital presenceFunctional Neuromodulation financial estimates
Financial estimateRevenue estimate
Valuation estimate
Functional Neuromodulation leadership team
Management profileNumber of profiles
Profiles1 record
Functional Neuromodulation funding detail
Funding detailFunding overview
Funding rounds1 record
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Functional Neuromodulation M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Functional Neuromodulation
What does Functional Neuromodulation do?
Functional Neuromodulation is a medical technology company developing neuromodulation technologies targeting cognitive and memory disorders. The company focuses on deep brain stimulation (DBS) approaches intended to treat conditions such as Alzheimer's disease and related cognitive impairments. The firm operates in the DBS device market, which is projected to reach $2.94 billion by 2030 at an 11.6% annual growth rate.
When was Functional Neuromodulation founded?
Functional Neuromodulation was founded in 2010. It employs 1 to 10 people.
Where is Functional Neuromodulation based?
Functional Neuromodulation is headquartered in Toronto, Canada, in the North America region.
Who are Functional Neuromodulation's main competitors?
Broad incumbents on record are Abbott, Medtronic, Boston Scientific and MicroPort Scientific. Direct peers are NeuroPace and LivaNova. Emerging players are Inspire Medical Systems, Axonics, Nevro and SetPoint Medical.
Does Functional Neuromodulation have an API?
No public API is recorded for Functional Neuromodulation.
What industry is Functional Neuromodulation in?
Functional Neuromodulation's product category is Deep Brain Stimulation Devices. Its primary akta.pro industry code is HLAHAEAK, Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS). Its NAICS code is 5417 and its SIC code is 3845.